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Abstract 
Many stroke survivors are affected by emotional and cognitive impairments that are difficult to 
treat. The current study uses a focal cortical ischemic stroke model called pial vessel disruption 
(PVD), which results in a non-reperfusion lesion in the right hemisphere. Previous studies have 
shown that PVD increases adenosine signalling, leading to the persistent stimulation and 
subsequent internalization of the adenosine A1 receptor (A1R), as well as the compensatory 
upregulation of the adenosine A2 receptor (A2AR) in the hippocampus. This adenosine receptor 
remodeling decreases cell surface expressions of the α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) glutamate receptor subunits GluA1 and GluA2, thereby 
impairing hippocampal long-term potentiation (LTP). Moreover, cognitive deficits along with 
depression- and anxiety-like behaviours are demonstrated by rats following PVD. To better 
understand how neural oscillations affect post-PVD cell signalling and behaviour, LFMS 
delivering GBOs (40 Hz) was applied once-daily for three days following PVD. The literature 
suggests that ischemic stroke desynchronizes hippocampal gamma oscillations (30-80 Hz). This 
range of neural frequencies underlie higher cognitive processes such as learning and memory. 
Hippocampal-dependent cognition is crucial for encoding healthy emotional memories. Thus, 
LFMS may be normalizing adenosine signalling and resynchronizing endogenous gamma 
oscillations to have an overall therapeutic effect on post-PVD behavioural changes. Indeed, three 
LFMS treatments improved various aspects of depression- and anxiety-like behaviours, as well as 
hippocampal-dependent spatial memory in rats that underwent PVD. Moreover, LFMS equalized 
LTP between the ipsilateral and contralateral hippocampi and protected both hemispheric regions 
from cell death and neurodegeneration. Based on these results, LFMS may have a neuroprotective 
effect through either decreasing extracellular adenosine concentrations, preventing persistent A1R 
stimulation, or decreasing the compensatory upregulation of A2AR in the hippocampus following 
PVD.  
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Chapter 1: Introduction 
1.1 Ischemic Stroke 
1.1 Introduction to Ischemic Stroke 
Stroke is one of the leading causes of death and disability worldwide (Johnson, Onuma, 
Owolabi, & Sachdev, 2016). Ischemic strokes are characterized by the occlusion of a brain arterial 
blood vessel due to a thrombus or embolus (Durukan & Tatlisumak, 2007). This leads to a 
deprivation of oxygen and nutrients to brain tissue. Although ischemic strokes account for 85-87% 
of all strokes, immediate treatment and diligent rehabilitation can save lives and effectively rescue 
functions (Bansal, Sangha, & Khatri, 2013). Depending on the size, location, and duration of vessel 
disruption, tissue plasminogen activator can lyse the clot and restore blood flow. In some cases, 
vessel disruption does not result in reperfusion and the ischemic lesion becomes permanent (Bansal 
et al., 2013). Regardless of its duration, ischemia can initiate downstream neurodegenerative 
signalling that affects the immediate injury site as well as other vulnerable brain regions such as 
the hippocampus. These disruptions give rise to mood disorders such as post-stroke depression 
(PSD) and post-stroke anxiety (PSA), as well as cognitive impairments. Rehabilitation may 
proceed over weeks to years, and commonly consist of pharmacotherapy, psychotherapy, and 
physiotherapy (NIH, 2018). Neuromodulatory therapies such as repetitive transcranial magnetic 
stimulation (rTMS) may also be effective by targeting downstream neurodegeneration from an 
electrophysiological standpoint (Al-Harbi & Qureshi, 2012; Tyler et al., 2008). 
1.1.2 Hippocampal Vulnerability in Ischemic Stroke  
The hippocampus is particularly vulnerable to ischemia (Schmidt-Kastner & Freund, 
1991). This could partly be due to its greatly elaborated vasculature supplying the Sommer’s sector 
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of the CA1, and its location between the carotid and vertebrobasilar arteries (Tatu & Vuillier, 
2014). In a study where monkey brains underwent 20 minutes of global ischemia followed by 
reperfusion, the motor cortex was significantly resistant to downstream neurodegeneration 
compared to the hippocampus (Zhu et al., 2012). Damage to the CA1 pyramidal neurons are of 
particular interest when it comes to ischemic stroke. In one study, transient focal ischemia 
selectively damaged the CA1 pyramidal neurons leaving the neurons of the CA3 and dentate gyrus 
intact (Harry & Lefebvre d'Hellencourt, 2003). Moreover, the loss of CA1 pyramidal neurons due 
to an ischemic stroke correlated with spatial memory deficits that were not observed after damage 
to the CA3 and dentate gyrus (Volpe, Davis, Towle, & Dunlap, 1992). As the hippocampus is 
responsible for a large spectrum of behaviours, ischemic damage to its neuronal populations may 
result in significant neurological and psychiatric symptoms such as cognitive deficits in 
hippocampal-dependent spatial memory, depression and anxiety.  
There are various cellular and molecular factors underlining these post-stroke psychiatric 
symptoms. Glutamatergic signalling may explain hippocampal vulnerability leading to spatial 
memory deficits, depression, and anxiety; as hippocampal interneurons are more resistant to 
excitotoxic insults compared to pyramidal cells, due to their glutamate receptor subunit 
composition (Kovalenko et al., 2006). Ischemia causes global increases in extracellular glutamate 
(Nishizawa, 2001), resulting in the reorganization of its receptor’s subunits throughout 
hippocampal synapses (M. Chen et al., 2008; Z. Chen et al., 2014). These glutamatergic changes 
disrupt hippocampal synaptic plasticity or LTP, which is believed to underlie cognitive processes 
such as learning and memory. Emotional regulation may also be affected as abnormal hippocampal 
structure and function are often observed in depression and anxiety (Chan et al., 2016).  
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1.1.3 Gamma Oscillation Desynchrony in Ischemic Stroke 
Network oscillations can be described as the electrical interaction and synchronous firing 
of spatially distinct excitatory and inhibitory neurons. These oscillations range from 0.05-500 Hz, 
which are further separated into smaller ranges that mediate specific psychophysiological 
functions. The two most prevalent ranges in the hippocampus are theta oscillations between 1-25 
Hz and gamma oscillations between 25-140 Hz. The latter is generated from either the entorhinal 
cortex feeding into the dentate gyrus or the CA1-CA3 region (Csicsvari, Jamieson, Wise, & 
Buzsaki, 2003). Gamma oscillations are responsible for cortical-hippocampal circuit-dependent 
cognition and its ensuing cognitive processes such as attention, learning, and memory (Colgin & 
Moser, 2010). As network oscillations relate to ischemic stroke, a recent comprehensive review 
stated that ischemia leads to rises in low frequency and drops in high frequency oscillations; or 
specifically a decrease in the alpha to delta oscillation ratio (Moyanova & Dijkhuizen, 2014). 
Whether this ischemia-induced oscillatory pattern specifically applies to the hippocampus remains 
unclear. Currently, there are no studies linking changes in hippocampal synaptic plasticity, 
hippocampal gamma oscillations and behaviour in post-stroke conditions.  
1.1.4 Hemispheric Differences in Ischemic Stroke 
A unilateral ischemic stroke may initiate different cellular mechanisms in the ipsilateral 
and contralateral brain regions. This is clearly demonstrated in the motor cortex, where 
compensatory synaptic plasticity in the contralesional motor cortex allows for the relocalization of 
lost functions (Caleo, 2015). Functional neuroimaging studies have demonstrated enhanced 
contralateral activity immediately after a stroke (up to 10 days) followed by increased activity in 
ipsilateral regions during the chronic stages of stroke recovery (Marshall et al., 2000; Ward, 
Brown, Thompson, & Frackowiak, 2003). Post-stroke hemispheric differences are also apparent 
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in the prefrontal cortex and hippocampus (Madinier et al., 2013). It was found that pro-brain-
derived neurotrophic factor (pro-BDNF) levels vary between hemispheres throughout the month 
following an ischemic stroke (Madinier et al., 2013). Not only does BDNF maintain synaptic 
plasticity, (Lu, Nagappan, & Lu, 2014), but it has been shown to be neuroprotective against oxygen 
and glucose deprivation (Van Kanegan et al., 2014). In an effort to equalize function between the 
hemispheres following a unilateral stroke, non-invasive neuromodulation has been used to either 
inhibit over-compensating contralateral regions or enhance insufficient ipsilateral regions (Di Pino 
et al., 2014; Grefkes & Ward, 2014). 
1.2 Post-Stroke Behavioural Changes  
1.2.1 Post-Stroke Depression 
Post-stroke depression (PSD) occurs in 30-35% of stroke patients as it is one of the most 
common stroke-associated psychiatric complications (Lenzi, Altieri, & Maestrini, 2008). Patients 
suffering from PSD have higher mortality rates during rehabilitation compared to those who are 
not depressed. Like major depression, PSD is treated with antidepressants such as selective 
serotonin reuptake inhibitors and tricyclic antidepressants. In a recent study involving 1450 
ischemic stroke patients, more than two thirds of those who were depressed (67.9%) were 
unresponsive to antidepressants (El Husseini et al., 2012). Other approved therapies such as 
neuromodulation in the form of non-invasive brain stimulation (NIBS) may be effective in these 
patients (Lenzi et al., 2008). For example, repetitive transcranial magnetic stimulation (rTMS) 
delivering frequencies higher than 20 Hz is regarded as a useful intervention for stroke-induced 
apathy (Sasaki et al., 2017). The unique pathophysiology of PSD provides itself as an opportunity 
for delineating the therapeutic mechanism of NIBS within this frequency range.  
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There are multiple pathophysiological factors or mechanisms within PSD. Lesion type, size 
and location are among the neuroanatomical factors. Pertaining to lesion location, there is 
conflicting data on whether it is predictive of the depressive symptoms that may result (Aben et 
al., 2006; Caeiro, Ferro, & Figueira, 2012; Snaphaan, van der Werf, Kanselaar, & de Leeuw, 2009). 
Other pathophysiological factors include: abnormal monoamine and glutamate signalling; 
neuroinflammation; stress on the hypothalamic-pituitary-adrenal axis; and reduced neurogenesis 
(Feng, Fang, & Liu, 2014). All of these factors are associated with the hippocampus, which is the 
brain region responsible for memory-dependent mood regulation. There is also evidence that PSD 
patients have very distinct patterns of hippocampal gamma oscillations compared to healthy 
individuals (Fitzgerald & Watson, 2018). However, it is difficult to generalize these patterns as 
they depend on the patient’s cognitive state during the measurement, as well as the specific 
hippocampal region or cell population from which the measurements are taken.  
1.2.1 Post-Stroke Anxiety 
Approximately 20-25% of stroke patients experience anxiety. A meta-analysis of 13 
studies including data from 2408 patients demonstrated a strong association between post-stroke 
anxiety (PSA) and PSD (Wright, Wu, Chun, & Mead, 2017). It is easy to imagine that many 
patients suffering from both psychiatric conditions are singularly prescribed antidepressants. 
Unlike depression, which tends to focus on loss, anxiety is often future oriented. In a recent study, 
phobic anxiety was found to be more common compared to generalized anxiety disorder in stroke 
patients (Chun, Whiteley, Dennis, Mead, & Carson, 2018). Aside from antidepressants, PSA 
patients may also be prescribed benzodiazepines or alpha-delta calcium channel convulsants 
(Farach et al., 2012). Currently, there are no neuromodulation studies that solely focus on PSA 
without the presence of PSD. However, rTMS delivering 20 Hz was found to significantly improve 
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symptoms in non-stroke patients with generalized anxiety disorder (Dilkov, Hawken, Kaludiev, & 
Milev, 2017). 
Anxiety arises from dysregulations in limbic structures such as the amygdala, which 
generates emotional and fear-related memories. The amygdala is heavily connected to cortical 
regions, as it receives inputs from the hippocampus, thalamus, and hypothalamus (E. I. Martin, K. 
J. Ressler, E. Binder, & C. B. Nemeroff, 2009). The hippocampus has tonic inhibitory control over 
the hypothalamic-pituitary axis. However, ischemic stroke presents as a stressor that overrules this 
tonic inhibition, leading to glucocorticoid secretion that exacerbates neuronal damage (Radak, 
Resanovic, & Isenovic, 2014). As it relates to network oscillations, anxiety-related stimulus is 
associated with strong gamma oscillations from the visual cortex, fusiform gyrus, amygdala, and 
hippocampus (Albrecht, Caliskan, Oitzl, Heinemann, & Stork, 2013; Schneider et al., 2018). There 
are no studies measuring gamma oscillations in humans or animals experiencing PSA. However, 
stroke-induced disruptions in gamma oscillations likely affect communication between the 
hippocampus and medial prefrontal cortex, which regulates anxiety in the form of theta-gamma 
oscillation coupling (Adhikari, Topiwala, & Gordon, 2010; Khemka, Barnes, Dolan, & Bach, 
2017; Padilla-Coreano et al., 2016). 
1.2.3 Post-Stroke Cognitive Impairment  
A cross-sectional study involving 10 countries and 6080 ischemic stroke patients suggested 
that more than 30% of these patients experienced cognitive impairment at some point throughout 
the five years following their stroke (Rist et al., 2013). The two most common forms of post-stroke 
cognitive impairment are aphasia and hemispatial neglect. Deficits in attention, learning, working 
memory, visual perception, and executive function (i.e. decision making, organization, problem 
solving) may also occur due to ischemic strokes (Gottesman & Hillis, 2010). Moreover, spatial 
7 
 
memory deficits are more frequent in right-hemispheric compared to left-hemispheric patients (De 
Renzi, Faglioni, & Previdi, 1977). There are an increasing number of studies using transcranial 
magnetic stimulation (TMS) to enhance cognition in not only those suffering from neurological 
and psychiatric disorders, but also in healthy individuals (Luber & Lisanby, 2014). Studies 
involving humans and animals have shown that frequencies in the 10-20 Hz range are effective in 
improving aspects of cognition such as working memory following an ischemic stroke (Guo, Lou, 
Han, Deng, & Huang, 2017; B. R. Kim, Kim, Chun, Yi, & Kwon, 2010).  
Post-stroke cognitive impairments manifest from a series of highly heterogenous 
pathological events (Brouns & De Deyn, 2009; Kalaria, Akinyemi, & Ihara, 2016). It is likely that 
disruptions in synaptic plasticity and gamma oscillations are products of these pathological events. 
There are a couple anatomical generators of gamma oscillations in the hippocampus. Outside of 
the hippocamps, slow gamma oscillations ranging from 25-30 Hz are generated from the entorhinal 
cortex. This entorhinal cortex provides or encodes spatial information (Hafting, Fyhn, Molden, 
Moser, & Moser, 2005), which is then stored in the CA3 region of the hippocampus (Brun et al., 
2002; Steffenach, Sloviter, Moser, & Moser, 2002). Altogether, oscillations from these regions 
provide a mode of input to the CA1 (Colgin et al., 2009). Optogenetic inhibition of the entorhinal-
hippocampal circuit reduces gamma oscillation synchrony, resulting in impaired execution during 
a spatial memory task (Yamamoto, Suh, Takeuchi, & Tonegawa, 2014). Thus, it is conceivable 
that stroke-induced disruptions in these circuits could also lead to hippocampal-dependent spatial 
memory impairments.  
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1.3. Mechanisms in PVD 
1.3.1. Introduction to PVD  
Pial Vessel Disruption (PVD) is a focal cortical ischemic stroke model that is conducted in 
rats. It entails a 5 mm diameter craniotomy on the right and rostral side of the bregma. The class I 
large-sized pial vessel gives rise to class II medium-sized pial vessels, which eventually penetrate 
the cerebral cortex. In PVD, a few of these medium-sized pial vessels are permanently disrupted, 
causing a non-reperfusion injury (Hua & Walz, 2006). Within the next two days, the 1 mm3 
ischemic lesion becomes filled with both infiltrating and resident immune cells (Cayabyab, 
Gowribai, & Walz, 2013; K. Wang & Walz, 2003). Over the next 21 days, this region becomes a 
fluid-filled lacuna-like cavity that is encapsulated by reactive astrocytes (Hua & Walz, 2006; K. 
Wang & Walz, 2003). Moreover, resident microglia become activated and secrete matrix 
metalloproteinase-2 and -9, which break down the endothelial cells of the blood-brain barrier. This 
allows peripheral immune cells, such as lymphocytes, macrophages, and neutrophils, to infiltrate 
the brain parenchyma and exacerbate neuroinflammation (Cayabyab et al., 2013; Fan, Lo, & 
Wang, 2013; Wei et al., 2013). PVD is a small vessel stroke model with unique neuroinflammatory 
and neurodegenerative properties.  
1.3.2 Adenosine-Mediated Glutamatergic Modulation in PVD 
Adenosine is a purine nucleoside with major neuromodulatory mechanisms. It is comprised 
of an adenine molecule attached to a ribose sugar that has the potential to be phosphorylated. 
Adenosine can bind to four G-protein-coupled adenosine receptor subtypes known as A1, A2A, 
A2B, and A3 (Collis & Hourani, 1993; Fredholm, Chen, Cunha, Svenningsson, & Vaugeois, 
2005). Its downstream signalling effects normal neuronal and glial functions (Fredholm et al., 
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2005), motor functions (El Yacoubi et al., 2000), executive functioning (de Mendonca & Ribeiro, 
1997), feeding (Lee, Li, Xi, Suh, & Martin, 2005), sleeping (Fredholm et al., 2005), and natural 
aging processes (Castillo et al., 2009; Costenla, Cunha, & de Mendonca, 2010). Due to adenosine’s 
basal inhibitory tone in the hippocampus, it has always been thought to be neuroprotective in the 
excitotoxic conditions following ischemia (Cunha, Canas, Oliveira, & Cunha, 2006; Rudolphi, 
Schubert, Parkinson, & Fredholm, 1992; Sebastião, de Mendonça, & Ribeiro, 2001). However, 
recent studies have revealed its neurodegenerative potential through prolonged A1R activation in 
ischemic stroke (Z. Chen et al., 2014).   
Aside from neuroinflammation at the immediate lesion site, PVD causes global increases 
in adenosine signalling that is matched by hippocampal neurodegeneration as soon as 48 hours 
after the ischemic stroke (Z. Chen et al., 2014). In both the ipsilateral and contralateral 
hippocampus, surface and total lysate expressions of A2AR are upregulated, while A1R levels are 
downregulated following PVD (Z. Chen et al., 2014). It was also suggested that A1R and A2AR 
signalling may be linked via serine/threonine protein kinase CK2 (Stockwell, Jakova, & Cayabyab, 
2017). As such, PVD leads to upregulation of A2AR (Z. Chen et al., 2014) and downregulation of 
CK2 (Chen & Cayabyab, unpublished). CK2 normally contributes to A2AR desensitization rate 
(Rebholz et al., 2009),  so the downregulation of CK2 is expected to mediate the observed A2AR 
upregulation during PVD.  
Another component in this neurodegenerative pathway is adenosine-mediated 
glutamatergic modulation. Excitotoxic neurodegeneration predominantly occurs through the N-
methyl-D-aspartate (NMDA) receptor of glutamate. However, A1R signalling was also found to 
affect the surface expression of two AMPA receptor subunits, GluA1 and GluA2 (Z. Chen et al., 
2014; Stockwell, Chen, Niazi, Nosib, & Cayabyab, 2016). PVD downregulates A1R and 
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upregulates A2AR, leading to the internalization of GluA1 and GluA2 in both the ipsilateral and 
contralateral hippocampus (Z. Chen et al., 2014). Moreover, this glutamatergic modulation, 
specifically through GluA1, was found to be dependent on protein phosphatase (PP) activation as 
adenosine-mediated glutamate receptor internalization was prevented by various PP inhibitors 
(Stockwell et al., 2016). A diagram illustrating all of the speculated signalling proteins and 
pathways involved in ischemia- or PVD-induced A1R and A2AR crosstalk, as well as adenosine-
mediated AMPAR modulation was recently published (Stockwell et al., 2017). Aspects of these 
pathways initiated by PVD may be therapeutic targets of GBOs delivered by LFMS. 
 
Figure 1.1 Proposed signalling pathway induced by A1R and A2AR activation following 
ischemia or PVD (Stockwell et al., 2017).  
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1.4 LFMS 
1.4.1 Introduction to LFMS 
LFMS is a subthreshold form of rTMS that has predominantly been investigated as a novel 
treatment for depression. Unlike rTMS, LFMS delivers lower electric field strengths that are less 
than 1 V/m (Shafi, Stern, & Pascual-Leone, 2014). These strengths cannot evoke action potentials; 
however, they may still affect synapses through dendritic excitability. In one study, field strengths 
of 1 V/m changed the membrane potential of a dendrite by 10 mV (Tranchina & Nicholson, 1986). 
LFMS operates in various magnetic parameters by adjustments in wave shape and temporal 
pattern. For example, the wave shape may be linear or uniform, while the magnetic stimulation 
may occur continuously or in pulses. Wave shape and direction targets specific cellular 
populations, while temporal pattern determines overall excitatory or inhibitory effects on synapses. 
The future of LFMS treatment entails matching these parameters to the desired 
electrophysiological effect within specific neurological and psychiatric disorders.  
Another key difference between rTMS and LFMS is spatial resolution. LFMS consists of 
coils that surround the entire scalp, simultaneously exposing all brain regions to the 
electromagnetic stimulation (Shafi et al., 2014). Mood and cognition are regulated through 
multiple brain regions. Therefore, targeting the neural network desynchronies of a single brain 
region may not be the most effective therapeutic approach in psychopathology. Despite this 
reasoning, there are many conflicting reports on the advantages of unilateral versus bilateral 
neuromodulation. In one study, bilateral rTMS was more effective compared to its unilateral rTMS 
for improving bipolar depression (Kazemi et al., 2016). As it pertains to ischemic stroke, rTMS 
delivering a frequency of 10 Hz and positioned perpendicular to the cortex and approximately 5 
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mm right from the bregma, enhanced hippocampal neogenesis and suppressed apoptosis, thereby 
improving cognition in rats that had undergone middle cerebral artery occlusion (Guo et al., 2017).  
1.4.2 Studies on LFMS to Date 
The earliest LFMS study serendipitously occurred when a 20-minute magnetic stimulation 
with echo-planar magnetic resonance spectroscopic imaging (EP-MRSI) rapidly elevated mood in 
bipolar patients (M. L. Rohan et al., 2014). Similar degrees of mood elevation were observed in a 
subsequent study using the same stimulation parameters but involving patients with major 
depression disorder and bipolar disorder (M. L. Rohan et al., 2014). In this study, field penetration 
calculations revealed that the strongest magnetic fields were experienced by the prefrontal and 
orbitofrontal cortices (M. L. Rohan et al., 2014). This makes sense because dendritic excitability 
within neuronal layers five and six of the cortex greatly affect mood due its complex networks and 
inputs to subcortical regions such as the hippocampus and amygdala (Ledergerber & Larkum, 
2010; Spruston, 2008). Another more recent study found that when MDD (Major Depressive 
Disorder) patients received LFMS in the gamma oscillation range of 7.5-12.5 Hz, their mood 
elevations were associated with a significant increase in serum brain-derived neurotrophic factor  
(BDNF), a neurotrophic factor critical for synaptic plasticity underlying e (Lu et al., 2014; Xiao et 
al., 2018). BDNF (Xiao et al., 2018).  
LFMS has also recently been applied to Alzheimer’s Disease (AD) models. As it relates to 
depression, up to 50% of AD patients experience depressed mood (Modrego, 2010) along with 
significant cognitive and memory deficits. In one study, applying LFMS for 40 minutes/day 
throughout eight weeks drastically attenuated amyloid β (Aβ) accumulation, restored hippocampal 
LTP, and improved cognition in amyloid precursor protein/presenilin-1 (5XFAD) mice (Zhen et 
al., 2017). In another study using 5FAX mice, gamma oscillations were optogenetically entrained 
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in the fast-spiking parvalbumin-positive interneurons. These entrainments induced genes 
associated with the morphological transformation of microglia, resulting in the co-localization of 
activated microglia and Aβ (Iaccarino et al., 2018). The question remains whether LFMS 
normalizes the electrophysiological aspects of AD, thereby restoring cellular and molecular 
pathology, or vice versa. 
1.5 Hypothesis 
It remains unclear whether GBOs delivered by LFMS can alleviate the emotional and 
cognitive impairments that occur following a focal cortical ischemic stroke. PVD is a non-
reperfusion hypoxic lesion that initiates neuroinflammation at the immediate lesion site (Cayabyab 
et al., 2013; K. Wang & Walz, 2003), as well as synaptic depression and secondary 
neurodegeneration in the hippocampus (Z. Chen et al., 2014). At the molecular level, PVD causes 
the release of adenosine leading to persistent A1R stimulation and subsequent remodeling of both 
adenosine and glutamate receptor subtypes. Hippocampal gamma oscillations are likely disrupted 
following PVD. The causal order in which these events occur remains unclear. Nonetheless, LFMS 
aims to resynchronize hippocampal gamma oscillations to improve the emotional and cognitive 
impairments that occur as a result of multiple pathological events. While LTP underlies learning 
and memory at the molecular level, gamma oscillations are considered the larger-scale 
phenomenon that occurs during these higher cognitive processes. Thus, gamma oscillations are 
dependent on LTP, which heavily relies on neuronal viability and function. Neuroinflammation 
and neurodegeneration determine this viability. The Y-maze, Open Field Test (OFT), and Forced 
Swim Test (FST) were conducted to measure the improvements in hippocampal-dependent spatial 
memory, anxiety, and depression, respectively. The chemically-induced LTP (cLTP) protocol 
confirmed whether resynchronizing hippocampal gamma oscillations reversed adenosine-
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mediated glutamatergic signalling to improve LTP. Finally, Propidium Iodide (PI) was used to 
quantify non-discriminant cell death, while Fluoro-Jade C (FJC) was stained for 
neurodegeneration in the hippocampus. Altogether, GBOs delivered by LFMS are hypothesized 
to be helpful in focal cortical ischemic stroke. 
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Chapter 2: Methods 
2.1. Ethics Statement  
All animals were treated according to guidelines of the Canadian Council for Animal Care 
(CCAC) under the supervision of the University of Saskatchewan Committee on Animal Care and 
Supply under the animal protocol approval number 20070090.  
2.2. Stereotaxic Surgery  
Male sprague dawley rats of approximately eight weeks of age were anesthetized with <2% 
isoflurane immediately after which they were subcutaneously injected with 0.03mL/kg of 
buprenorphine for pain management. For the PVD surgery, rats then underwent a 5 mm-diameter 
craniotomy on the right and rostral side of the bregma adjacent to the coronal and sagittal sutures. 
Once the dura was peeled back, Class II pial vessels were cut or permanently disrupted using fine-
tipped forceps. Bleeding was controlled with ice-cold saline. The skull piece was then placed back, 
and the wound was sutured.  Sham rats received the same treatment with dura removal but no 
vessel disruption.  
2.3. LFMS Treatments  
Rats were placed in a 30 x 15 x 15 cm mouse cage to be set up in the LFMS machine. For 
the Sham-LFMS treatment, the machine was plugged in and turned on, however, the stimulation 
was not initiated. For the LFMS treatment, the machine was turned on and the stimulation was 
initiated. Throughout the 20-minute stimulation, the electromagnetic waves occurred for two 
seconds every four seconds of rest. Throughout these two seconds, the wave pattern switched back 
and forth between Uniform and Linear patterns. The frequency of the stimulation was 40 Hz and 
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the electromagnetic field strength was approximately 1 V/m. Moreover, the stimulation was 
applied to the entire body, during which rats roamed freely in their cages.   
2.4. Behaviour Testing 
2.4.1 Y-maze 
The Y-maze tests rodent’s innate curiosity to explore spatially novel areas. It presents no 
negative or positive reinforcers and is minimally stressful for the rodents (Conrad, Galea, Kuroda, 
& McEwen, 1996). Success in this behaviour test is associated with hippocampal-dependent 
spatial memory, while poor Y-maze performance can be indicative of abnormal hippocampal 
pyramidal cell and dendrite networks (Conrad et al., 1996). The Y-maze was used to determine 
whether three LFMS treatments over three days improved PVD-induced damage to hippocampal-
dependent spatial memory.  
Y-maze apparatus consists of three arms that are joined by a triangle-shaped center to form 
a “Y” shape. Each arm has a rectangular base that is 45 x 12 cm, and all areas of the maze are 
surrounded by 35 cm tall walls. In the first trial, one of the three arms were blocked off. Rats were 
then placed in the maze for 15 minutes and free explore the start arm and the old arm, but not the 
blocked off novel arm. After the first trial, rats were placed back in their cages for a 90-minute 
break. In the second trial, rats were placed in the maze for five minutes and free to explore all arms 
including the recently unblocked novel arm. For both trials, there were spatial cues on the walls 
outside the maze for rats to easily view throughout their exploration periods. A video camera was 
used to record both trials. The Y-maze was the first of three behaviour tests conducted on the third 
experimental day.  
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A total of 48 rats underwent the Y-maze. There were 12 rats in each of the four treatment 
groups (n=12). This n-value is typical for seeing significant differences in behaviour studies on 
rats. The treatments of the rats were unknown or blinded throughout the Y-maze testing and 
subsequent analysis to minimize observer bias.  
The video-tracking software, EthoVisionXT (Noldus) was used to automatically score the 
following: time spent in the start arm (s), time spent in the old arm (s), time spent in the novel arm 
(s), total distance travelled (cm), and velocity of movement (cm/s). These scores were determined 
for the second 5-minute trial. Time spent in each of the arms were calculated as a percentage of 
the total trial time. GraphPad Prism 6.0 (GraphPad) was used to construct all the graphs that were 
presented as a mean + SEM for each of the four treatment groups. GraphPad InStat version 6.0 
(GraphPad) was used to apply a one-way ANOVA and a Tukey Kramer post-hoc test to determine 
statistical significance.  
2.4.2 Open Field Test 
Anxiety levels which may affect a rodent’s willingness to explore an unfamiliar 
environment can be measured by the open-field test (OFT). The tendency of rodents to travel close 
to the walls and not enter the center, lit areas of the OFT apparatus is termed as thigmotaxis. It is 
unclear which brain regions mediate the specific behaviours within the OFT. Multiple regions and 
networks are likely involved, including the limbic areas controlling emotionality and fear, and 
higher neocortical regions controlling exploration and motor activity (Elizabeth I. Martin, Kerry 
J. Ressler, Elisabeth Binder, & Charles B. Nemeroff, 2009). Aside from anxiety, the OFT can be 
used to measure locomotion. In the current study, OFT was used to determine how LFMS affects 
emotional and physical functioning following PVD.  
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The OFT apparatus is a 56 x 56 cm square-shaped field surrounded 57 cm tall walls. The 
bright light that shines directly above the maze causes the 280 x 280 cm center square to be the 
brightest and most exposed area of the field. Rats were initially placed in this center square and 
free to explore the entirety of the field for 15 minutes. A video camera was used to record their 
behaviour. The open-field test was conduced after the Y-maze on the third day of experimentation.  
A total of 48 rats underwent the OFT. There were 12 rats in each of the four treatment 
groups (n=12), which is the expectant number for seeing significant differences in behaviour 
studies on rats. To best eliminate bias, the treatments of the rats were unknown or blinded 
throughout the OFT testing and its subsequent analysis on EthoVisionXT.  
EthoVisionXT (Noldus) was used to automatically score the following: center square 
entries, center square duration (s), distance travelled (cm), and velocity of movement (cm/s). All 
graphs were constructed using GraphPad Prism 6.0 (GraphPad) where scores were presented as a 
mean + SEM for every treatment group. Statistical significance was assessed using GraphPad 
InStat version 6.0 (GraphPad) where a one-way ANOVA and a Tukey Kramer post-hoc test were 
applied. 
2.4.2 Forced Swim Test 
The forced swim test (FST) is behaviour test that measures depressive symptoms such as 
despair and learned helplessness. When rodents are first placed in water, they are expected to swim 
as vigorously as possible to escape this stressful situation (Yankelevitch-Yahav, Franko, Huly, & 
Doron, 2015). As time passes, they reach a point of helplessness and despair, which is reflected by 
immobility or moving just enough to balance and keep their heads above the water to breathe 
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(Yankelevitch-Yahav et al., 2015). The FST was used to determine whether LFMS alleviated 
depressive symptoms in rats that had undergone PVD.  
The FST apparatus is a 30 x 30 x 60 cm rectangle-shaped acrylic glass container that is 
two-thirds filled with water of 25°C (Yankelevitch-Yahav et al., 2015). Rats were placed in the 
container for 10 minutes, during which their behaviour was recorded by a video camera. The FST 
was the last of three behaviour tests conducted on the third experimental day.  
A total of 48 rats underwent the FST. There were 12 rats in each of the four treatment 
groups (n=12). As previously mentioned, this number is typical for seeing significant differences 
in behaviour studies on rats. It was unknown which rat belonged to which treatment group as they 
were being tested in the FST. This blinding continued throughout behaviour analysis using 
EthoVisionXT. 
The video files were uploaded to EthoVisionXT (Noldus), which automatically scored for 
two activity statuses throughout the test. The highly active and inactive statuses were separated by 
threshold of 0.15% of the total activity. All graphs were constructed using GraphPad Prism 6.0 
(GraphPad) where scores were presented as a mean + SEM for every treatment group. Statistical 
significance was assessed using GraphPad InStat version 6.0 (GraphPad) where a one-way 
ANOVA and a Tukey Kramer post-hoc test were applied. 
2.5. Hippocampal Slice Preparation 
Eight-week-old sprague dawley rats were anesthetized with halothane then quickly 
decapitated. The brains were excised then submerged in an ice-cold oxygenated high-sucrose 
dissection medium containing the following (in mM): 87 NaCl, 25 NaHCO3, 25 glucose, 75 
sucrose, 2.5 KCl, 1.25 NaH2PO4, 7.0 MgCl2, and 0.5 CaCl2 (Brust, Cayabyab, & MacVicar, 
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2007). Hippocampus-containing slices were taken at 400 µm thickness using a vibrating tissue 
slicer or vibratome (VTS1200S, Vibram Instruments, Germany). Slicing occurred in the same ice-
cold oxygenated high-sucrose dissection medium as described above. For the next hour in room 
temperature, hippocampal slices were submerged in oxygenated artificial cerebral spinal fluid 
(aCSF) containing the following (in mM): 126 NaCl, 2.5 KCl, 2.0, MgCl2, 1.25 NaH2PO4, 26 
NaHCO3, 10 glucose, 2.0 CaCl2 (Brust et al., 2007). Oxygenation was accomplished by 
continually aerating the solution with 95% O2/5% CO2. 
2.6. Electrophysiology 
Electrophysiological recordings from acute hippocampal slices are a way to measure the 
sensitivity of spontaneously evoked electrical signal transmissions to various neuronal 
manipulation such as pathologies and treatments. These recordings allow us to study synaptic 
plasticity (a measure of synaptic efficacy or synaptic strength), which could regulate the 
neurophysiological basis of learning and memory. Chemically-induced long-term potentiation 
(cLTP) mimics spontaneous LTP to allow measurements of maximally reaching and sustained 
field excitatory postsynaptic potentials (fEPSPs) throughout 1 hour. As such, the fEPSPs of healthy 
control slices are expected to be higher during both cLTP and washout periods compared to slices 
sustaining neurological injuries such as ischemic stroke and hypoxia.   
Hippocampal slices were submerged in an electrophysiology recording chamber with 
constant perfusion of room temperature oxygenated aCSF (3 ml/min). The fEPSPs were evoked 
by orthodromic stimulation of the Schaffer collateral pathway using a bipolar tungsten stimulating 
electrode. These fEPSP signals were digitized at 10kHz using Digidata 1440A interface board and 
analyzed using Clampfit 9.0 (Axon Instruments, Foster City, CA). A recording microelectrode 
filled with aCSF was placed in the CA1 stratum radiatum. 
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Throughout each experiment, fEPSPs were evoked for 0.1 ms every 30 seconds. The 
stimulation amplitude for fEPSP was determined based on the maximum amplitude found for each 
hippocampal slice following a 20-minute equilibration period. It was then reduced until fEPSPs 
were approximately a third of the maximum value. The baseline recordings were for at least 10 
minutes. A treatment of Forskolin (50 µM)/Rolipram (0.1 µM) was perfused in aCSF that lacked 
Mg2+. Forskolin is an adenylyl cyclase (AC) activator, which ultimately increases extracellular 
cyclic adenosine monophosphate (cAMP) levels. Rolipram is a selective phosphodiesterase-4 
inhibitor that prevents the breakdown of cAMP thereby increasing its extracellular levels. 
Collectively, forskolin and rolipram promote intracellular LTP mechanisms through cAMP.  The 
cLTP induction was followed by a 1-hour washout period in aCSF that contained Mg2+. Synaptic 
plasticity during the washout period was not NMDA-dependent as this receptor was blocked by 
Mg2+ provided by the aCSF solution. The fEPSP slopes were normalized to the mean of 10 sweeps 
(five minutes). 
The n-values for the ipsilateral PVD & Sham-LFMS and PVD & LFMS treatment groups 
were 13 and four, respectively. The n-values for the contralateral PVD & Sham-LFMS and PVD 
& LFMS treatment groups were five and four, respectively. The n-value for the Naïve & LFMS 
treatment group was three. GraphPad Prism 6.0 (GraphPad) was used to construct all of the graphs, 
where %fEPSPs were presented as a mean + SEM for every treatment group. Statistical 
significance was assessed using GraphPad InStat version 6.0 (GraphPad) where a one-way 
ANOVA and a Tukey Kramer post-hoc test were applied. 
2.7 Propidium Iodide Staining 
Propidium iodide (PI) is a fluorescent marker for non-discriminant cell death. It cannot 
transverse cells that possess intact plasma membranes, therefore, it only binds to the DNA of dead 
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cells with damaged plasma membranes. Wavelengths between 400 nm and 600 nm (green light) 
excite PI molecules to emit red fluorescence between 600 nm and 700 nm. This marker was used 
to determine whether PVD-induced cell death can be prevented by three LFMS treatments. 
A total of 12 rats (three rats per treatment group) were dedicated to PI staining. Fresh 
hippocampal slices were incubated for 1 hour in a solution containing room-temperature aCSF and 
5µg/mL PI. The subsequent procedures were performed in the dark to prevent photobleaching. 
Following 1-hour incubation, slices were rinsed thoroughly in 1X Phosphate-buffered saline (PBS) 
then fixed in 4% paraformaldehyde (PFA) at 4°C overnight. The next day, slices were rinsed 3 x 
15 minutes in 1 X PBS, then mounted on gelatin-coated microscope slides (VWR, USA) and sealed 
using Prolong Gold Antifade Reagent (Invitrogen, USA) 
The slides containing PI-stained hippocampal slices were imaged using a Zeiss LSM700 
laser scanning confocal microscope (Carl Zeiss, Germany). A green light (543 nm) was used to 
induce PI fluorescence. The 10x objective lens was used to image the whole hippocampus in 
consecutive pieces. The CA1 pyramidal neurons were imaged using a Zeiss Plan-Apochromat 
63x/1.6 oil objective lens (Carl Zeiss, Germany). This lens captured z-stack images of 2 µm 
thickness at 200 µm depth into the hippocampus. Two z-stacks along the CA1 were taken per slice, 
which were then averaged using densitometry analysis.  
The Zeiss Zen 2009 version 5.5 software (Carl Zeiss, Germany) yielded the data for 
densitometry analysis using ImageJ (NIH). As z-stack images towards the outer top and bottom of 
the hippocampal slice sustained the most damage from the slicing procedure, the inner-most 20 
µm (~100 µm into the slice) segments were combined as a maximum intensity projection image. 
The mean intensity of this image was measured, averaged for each slice and treatment group, then 
normalized to the control group. Data was graphed as a percentage of the control group (100%) 
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for statistical analysis. Images collected from the 10x objective lens were assembled as montages 
of the whole hippocampus using Adobe Photoshop CS6 (Adobe Systems, Mountain View, CA).  
GraphPad Prism 6.0 (GraphPad) was used to construct all of the graphs, where PI intensity 
was presented as a mean + SEM for every treatment group. Statistical significance was assessed 
using GraphPad InStat version 6.0 (GraphPad) where a one-way ANOVA and a Tukey Kramer 
post-hoc test were applied. 
2.8 Fluoro-Jade C Staining 
Fluoro-Jade C (FJC) is a fluorochrome derived from fluorescein that stains all degenerating 
neurons regardless of the mechanism of insult or neurodegeneration. The maximum excitation and 
emission wavelengths for FJC are 485 nm and 525 nm, respectively. Unlike PI, FJC was used to 
determine whether LFMS prevented or reversed neuronal death or neurodegeneration.    
A total of 12 rats (three rats per treatment group) were used for FJC. All rats were first 
anesthetized, perfused, and their brains sliced. Rats were anesthetized with <2% isoflurane then a 
series of skin and diaphragm cuts exposed their hearts. As a needle infused 4% PFA into the left 
ventricle, the right atrium was cut to allow blood to flow out of the body. The PFA perfusion lasted 
for approximately 20 minutes. After the perfusion, the brain was removed and post-fixed in 4% 
PFA in 0.1 M PBS overnight. Brains were then stored in 30% sucrose (w/v) in 0.1 M PBS for an 
additional 3 days. Once the brains sunk to the bottom of the sucrose and PBS solution, they were 
frozen using solid carbon dioxide. Tissue Tek OCT mounting medium was used to mount the brain 
on a microtome (Leica Biosystems, Germany) for slicing. Slices were taken at 400 µm thickness 
then stored in Millonig's Phosphate Buffer at 4°C.  
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For the FJC staining process, the perfused hippocampal slices were first mounted on 
gelatin-coated microscope slides (VWR, USA). The mounted slices were then immersed in 70% 
ethanol, washed three times (one minute each time) with double-distilled water (ddH20), and 
immersed in 0.06% KMNO4 for 15 minutes. The slices were then washed again in ddH20 (three 
times, one minute each time) and stained with 0.001% FJC (Millipore Bioscience Research 
Reagents) for 20 minutes. The subsequent steps were performed in the dark to prevent 
photobleaching. Slices were washed for the last time in ddH20 (3 times, one minute each time) 
then dried in 4°C overnight. The mounted slices were rinsed in xylene and cover-slipped using 
Prolong Gold Antifade Reagent (Invitrogen). 
A Zeiss LSM700 laser scanning confocal microscope (Carl Zeiss, Germany) was used to 
image the slides containing FJC-stained hippocampal slices. A green light (488 nm) was used to 
induce FJC fluorescence. The whole hippocampus was imaged in consecutive pieces using the 10x 
objective lens. Alternatively, the CA1 pyramidal neurons were imaged using a Zeiss Plan-
Apochromat 63x/1.6 oil objective lens (Carl Zeiss, Germany). This lens captured z-stack images 
of 2 µm thickness at 200 µm depth into the hippocampus. Each slice provided two z-stacks along 
the CA1, which were then averaged using densitometry analysis.  
Data was yielded through the Zeiss Zen 2009 version 5.5 software (Carl Zeiss, Germany), 
which was then densitometrically analysed using ImageJ (NIH). As z-stack images towards the 
outer top and bottom of the hippocampal slice sustained the most damage from the slicing 
procedure, the inner-most 20 µm (~100 µm into the slice) segments were combined as a maximum 
intensity projection image. The mean intensity was calculated for each image, and these values 
were averaged for each animal and treatment group. After each treatment group mean was 
normalized to the control group mean, data was graphed as a percentage of the control group 
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(100%). Images collected from the 10x objective were assembled as montages of the whole 
hippocampus using Adobe Photoshop CS6 (Adobe Systems, Mountain View, CA).  
GraphPad Prism 6.0 (GraphPad) was used to construct all of the graphs, where FJC 
intensity was presented as a mean + SEM for every treatment group. Statistical significance was 
assessed using GraphPad InStat version 6.0 (GraphPad) where a one-way ANOVA and a Tukey 
Kramer post-hoc test were applied. 
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Chapter 3: Results 
3.1 Behaviour Testing  
3.1.1 LFMS on depressive behaviour measured by the FST 
The earliest LFMS studies focused on rapidly improving mood in patients with bipolar and 
major depressive disorders (M. Rohan et al., 2004; M. L. Rohan et al., 2014). Depressed mood is 
not limited to psychiatric disorders. Nearly 30% of stroke survivors experience depression 
(Paolucci, 2008), yet there are currently no studies on GBOs or LFMS in the gamma frequency 
range being applied to PSD. To better understand the therapeutic mechanism of LFMS, rats that 
underwent PVD received three once-daily LFMS treatments.  The FST was one of three behaviour 
tests conducted on the fourth day of the study. This test was conducted last to prevent its stresses 
from impacting the other two tests. As such, the GBOs delivered by LFMS was hypothesized to 
lessen helplessness and despair in rats experiencing depression following PVD.    
LFMS drastically improved immobility scores in the FST. As expected, the PVD & Sham-
LFMS group displayed the shortest latency to immobility (Figure 3.1a) and the longest time spent 
immobile (Figure 3.1a). These results demonstrate that PVD is a reliable model for studying the 
depressive behaviour that occurs as early as three days after an ischemic stroke. Compared to the 
PVD & Sham-LFMS group, the PVD & LFMS group spent significantly less time immobile 
(Figure 3.1b) and more time swimming or struggling before reaching immobility (Figure 3.1a). 
The exact mechanism by which GBOs improve depressive behaviour is unknown. Various 
parameters of NIBS have been found to be effective in depression. By understanding the 
mechanisms of these electrical, spatial, and temporal parameters, they can be used to target specific 
aspects and patterns of depressive behaviour  
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Figure 3.1 LFMS improved immobility scores indicating learned helplessness and despair in 
the PVD & LFMS group. (a, b) Rats were placed in a container of water for 10 minutes, and time 
spent immobile was calculated as a percentage of the total trial time. Latency to immobility was 
plotted as times in seconds. (a) The PVD & Sham-LFMS group displayed the largest percentage 
of time spent immobile compared to all other groups. LFMS treatment significantly decreased this 
percentage in rats that underwent PVD. (b) The PVD & Sham-LFMS group had the lowest latency 
to immobility score compared to all other groups. LFMS treatment significantly restored this 
latency to immobility. n=12 for each treatment group. n=12 for each treatment group. Values are 
shown as mean + SEM. Significance values: *= p<0.05, **= p<0.01. 
3.1.2 LFMS on anxious behaviour measured by the OFT 
Depression and anxiety often present together following a stroke (Schöttke and Giabbiconi, 
2015). It has been previously shown that a single LFMS treatment improves both depressive and 
anxious behaviour in patients suffering from bipolar and major depressive disorders (M. L. Rohan 
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et al., 2014). This study gave reason for applying LFMS to post-traumatic stress disorder (M. 
Rohan, 2015). which is primarily an anxiety disorder involving depressive episodes (American 
Psychiatric Association, 2013). In order to characterize the effects of GBOs on PSA, the OFT was 
conducted after the Y-maze and before the FST on the fourth day of the current study. The 
stimulation was hypothesized to lessen anxiety-like behaviour thereby encouraging center square 
exploration in rats experiencing PSA.  
There were no significant differences between any of the groups with regards to either 
center square entries of duration (Figure 3.2a, b, c, d, e, f). However, the PVD & Sham-LFMS 
group showed slightly decreased center square entries and duration compared to the Sham-PVD 
& Sham-LFMS group (p=0.9424) and the Sham-PVD & LFMS group (p=0.0756). These data 
trends are telling of anxious behaviour. The PVD & Sham-LFMS group displayed lower center 
square entries compared to the two LFMS groups; as well as the lowest center square duration 
compared to all other groups (Figure 3.2c, e, f). GBOs seemed to restore center square entries and 
duration in rats that underwent PVD (Figure 3.2d, e, f). A statistical power analysis will be able to 
calculate the number of n-values required to make these results significant. It must also be kept in 
mind that center square entries are a less reliable measure of exploratory behaviour. Rats may enter 
the center square while moving from wall to wall. All in all, LFMS may have a moderate anxiolytic 
effect on rats that underwent PSA.   
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Figure 3.2 LFMS seemed to restore center square entries and duration in the PVD & LFMS 
group. (a-f) Rats were placed in the brightly lit OFT for 15 minutes, during which they were free 
to explore. All durations were calculated as a percentage of the 15-minute trial. (c, e) Although the 
PVD & Sham-LFMS group entered the center square the least compared to the other groups, these 
comparisons were not significant. (c, e) The PVD & Sham-LFMS group displayed the lowest 
center square duration compared to the two Sham-PVD groups. (d, f) LFMS increased center 
square duration in the PVD & LFMS group, however, this increase was not significant. n=12 for 
each treatment group. n=12 for each treatment group. Values are shown as mean + SEM. 
Representative heat maps from each treatment group were acquired on EthoVision. 
3.1.3 PVD and LFMS on locomotion measured by the OFT 
It is unknown whether PVD or LFMS causes locomotive changes. Many stroke models do 
impair motor skills to some degree. However, the PVD model focuses on hippocampal 
functionality and one study was able to show that hippocampal lesioning does not affect the 
acquisition of a motor learning tasks (Gould et al., 2002). Nevertheless, it is important to rule out 
any PVD-induced motor impairments in order to properly interpret the other behaviour tests. As it 
pertains to LFMS, gamma oscillations have been linked to higher running velocities. For instance, 
faster running velocities were associated with large, systematic increases in the frequency of 
network oscillations ranging from the 30-120 Hz (Ahmed & Mehta, 2012). In the current study, 
mean velocity and distance travelled in the OFT were two measurements used to confirm whether 
PVD or LFMS significantly affected locomotion.  
There were no differences in mean velocity or distance travelled between any of the groups 
(Figure 3.3a, b). As the 1-mm3 PVD lesion does not penetrate deeper than the cerebral cortex, it 
was not expected to have a significant effect on motor skills. There was a trend where the Sham-
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PVD & LFMS (p=0.054, p=0.5205) and PVD & LFMS (p=0.0564, p=0.5319) group moved faster 
compared to those that received Sham-LFMS (Figure 3.3a). These groups also covered more 
distance compared to the Sham-LFMS groups (p=0.2683, p=0.3508, p=0.9982, p=0.6775) (Figure 
3.b). A statistical power analysis must be conducted to determine whether more n-values are 
required to solidify this trend. There is accumulating evidence that NIBS is therapeutic in stoke, 
as well as a variety of other neurological disorders involving motor deficits (Belci, Catley, Husain, 
Frankel, & Davey, 2004; Benninger et al., 2011; Freitas, Mondragon-Llorca, & Pascual-Leone, 
2011; Webster, Celnik, & Cohen, 2006). As the focus of the current study is on post-stroke 
cognitive and emotional impairments, it can be confirmed that neither PVD nor LFMS have motor 
effects that may take away from these focuses.   
 
Figure 3.3 Locomotor activity measured by mean velocity and distance travelled was not 
affected by PVD, nor was it significantly enhanced by LFMS treatment. (a, b) Rats were 
placed in the brightly lit OFT for 15 minutes, during which they were free to explore. (A) Although 
both LFMS groups displayed higher mean velocities compared to the Sham-LFMS groups, these 
differences were not significant. (b) All distance scores resembled the trends in (a), where the 
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Sham-PVD & LFMS and PVD & LFMS groups travelled the most distance on average. n=12 for 
each treatment group. n=12 for each treatment group. Values are shown as mean + SEM.  
3.1.4 LFMS on hippocampal-dependent memory measured by the Y-maze 
Aside from depression and anxiety, ischemic stroke patients may also suffer from cognitive 
impairments related to episodic memory, working memory, attention and executive functioning 
(Dotson et al., 2014). The Y-maze was used to evaluate exploratory behaviour within the context 
of hippocampal-dependent spatial memory. It was the first of three behaviour tests conducted 
following the third and final LFMS treatment. This particular order of behaviour testing prevented 
the other two more stressful tests from impacting the rats’ cognitive performance in the Y-maze. 
GBOs delivered by LFMS was hypothesized to restore novel arm duration, indicating improved 
hippocampal-dependent spatial memory in rats that had undergone PVD.  
The only significant difference in this experiment was between the control, represented by 
the Sham-PVD & Sham-LFMS group, and the PVD & LFMS group in novel arm duration (Figure 
3.4a, d, g). The PVD & Sham-LFMS group was the least able to distinguish the novel arm from 
the other arms, which makes sense because rats in this group sustained the worst neurological 
injury and received no treatment thereafter (Figure 3.4c, g). Despite the lack of significant 
differences between the two PVD groups in any of the arm durations, there was a trend where the 
LFMS group spent more time in the novel arm and less time in the old arm, indicating improved 
hippocampal-dependent spatial memory compared to its Sham-LFMS counterpart (p=0.5259) 
(Figure 3.4c, d, f, g). More n-values are required to better understand these results. Nonetheless, 
gamma oscillations have been shown to improve cognitive in other neurodegenerative models such 
Alzheimer’s Disease (Mably & Colgin, 2018; Zhen et al., 2017).  
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Figure 3.4 LFMS did not significantly improve novel arm duration in the PVD & LFMS 
group. (a-g) After a 90-minute break, rats were placed back in the Y-maze for the second trial of 
five minutes. Arm durations were calculated as a percentage of the 5-minute trial. (c, g) The PVD 
& Sham-LFMS group generally spent the least amount of time in the novel arm compared to all 
other groups, especially the Sham-PVD & Sham-LFMS group. (a, g) There were no other 
significant differences between the groups. However, there was a trend where the PVD & LFMS 
group spent more time in the novel arm and less time in the old arm compared to the PVD & Sham-
LFMS group. n=12 for each treatment group. n=12 for each treatment group. Values are shown as 
mean + SEM. Representative heat maps from each treatment group were acquired on EthoVision. 
3.2 LFMS on hippocampal synaptic plasticity 
As previously mentioned, the hippocampus is particularly vulnerable to ischemic stroke. 
This vulnerability may present as impairments in LTP or synaptic depression (Li et al., 2013). In 
the case of a unilateral hypoxic lesion, the ipsilateral and contralateral hippocampi (relative to the 
lesion) may exhibit different patterns of LTP. For the cLTP experiments, the PVD & Sham-LFMS 
and PVD & LFMS groups were further separated into ipsilateral and contralateral groups. An extra 
treatment group called “Naïve & LFMS” was also added. This group did not undergo any surgical 
intervention but still received the three once-daily LFMS treatments. The purpose of the Naïve & 
LFMS group was to assess how GBOs affect healthy controls.  All in all, both PVD groups were 
expected to display hemispheric differences in LTP during the cLTP and washout periods. 
Moreover, the ipsilateral and contralateral PVD & LFMS groups were expected to resemble the 
Naïve & LFMS group more than its Sham-LFMS counterparts.  
The contralateral PVD & Sham-LFMS group reached the highest fEPSPs during the cLTP 
compared to all other groups (Figure 3.5a, b, d, e). During washout, the contralateral PVD & Sham-
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LFMS sustained LTP better than the ipsilateral PVD & Sham-LFMS group (Figure 3.5a, b, d, e). 
There were no differences in fEPSPs during either cLTP or washout amongst the PVD & LFMS 
groups (Figure 3.5a, c, d, e). The ipsilateral and contralateral PVD & LFMS group was also very 
similar to the Naïve & LFMS group throughout the experiment (Figure 3.5a, c, d, e). These results 
demonstrate that PVD causes major hemispheric differences in LTP, while GBOs equalize these 
differences to make both hemispheres resemble the Naïve & LFMS group. There have been NIBS 
studies with a similar goal, where they applied higher frequencies (>3 Hz) to the ipsilateral cortex 
to increase excitability and lower frequencies (≤1 Hz) to the contralateral cortex to decrease 
excitability (Kubis, 2016).  
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Figure 3.5 PVD and LFMS had different effects on synaptic plasticity in the ipsilateral and 
contralateral hippocampus. fEPSPs were evoked in the Schaffer collateral pathway while a 
recording electrode was placed in the CA1 stratum radiatum. A solution of Forskolin and Rolipram 
was perfused in aCSF. This cLTP induction was followed by a 1-hour washout period. (a, b, d, e) 
The contralateral PVD & Sham-LFMS group exhibited the highest fEPSPs during cLTP. This 
group better sustained LTP better than its ipsilateral counterpart throughout washout. Compared 
to the Naïve & LFMS group, the contralateral PVD & Sham-LFMS group reached higher 
potentials during cLTP but similarly sustained LTP during washout. (a, c, d, e) There were no 
differences in fEPSPs between the ipsilateral and contralateral PVD & Sham-LFMS group during 
either cLTP or washout. These groups exhibited fEPSPs that were similar to the Naïve & LFMS 
group all throughout the experiment. N varied from three to 13 for each treatment group. Values 
are shown as mean + SEM. Significance values: *= p<0.05, **= p<0.01. Trace images were 
produced using OriginLab.  
3.3 LFMS on non-discriminant cell death in the hippocampus  
Various neuroprotection studies have made the links between hippocampal cell viability, 
LTP, and cognition (Yabuki & Fukunaga, 2013; Yang, Yao, Chen, & Zhang, 2014). PVD causes 
changes in adenosine and glutamate signalling, leading to synaptic depression and 
neurodegeneration in the hippocampus (Z. Chen et al., 2014). PVD induces hypoxia leading to 
persistent A1R stimulation (Z. Chen et al., 2014). Therefore, both hypoxia and A1R agonism was 
shown to cause significant hippocampal cell death that was reversible by A1R antagonism 
(Stockwell et al., 2016). In the current study, hippocampal slices were incubated in Propidium 
Iodide for one hour before being fixed in paraformaldehyde, cover-slipped, and imaged using a 
Zeiss LSM700 laser scanning confocal microscope. Considering the behaviour and 
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electrophysiology data, GBOs were expected to differentially lessen cell death in the ipsilateral 
and contralateral hippocampus. 
Ipsilateral to the lesion, LFMS significantly reduced red fluorescence or cell death in slices 
that sustained PVD injury (Figure 3.6a, c). Moreover, this reduction in cell death was comparable 
to the time control and Sham-PVD & LFMS (Figure 3.6a, c). Contralateral to the lesion, the PVD 
& Sham-LFMS group displayed much less cell death compared to its ipsilateral counterpart 
(Figure 3.6b, d). However, LFMS was still successful in significantly reducing contralateral cell 
death (Figure 3.6b, d). These hemispheric differences in hippocampal cell death support the 
electrophysiology data, where there are different synaptic plasticity mechanisms between the 
ipsilateral and contralateral hippocampus. More research must be done to delineate the mechanistic 
links between LTP and cell death in each hemisphere following PVD.  
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Figure 3.6 LFMS treatment reduced cell death in both the ipsilateral and contralateral sides 
of the PVD lesion. (a-d) Fresh hippocampal slices were stained with PI then imaged with 10x and 
63x objective lenses. (a, c) The right panel contains montages of the whole hippocampus, while 
the left panel contains combined Z-stack images of the CA1. (b, d) Bar graphs showing mean 
densitometry values normalized to the time control value (100%). (a, b) Amongst the ipsilateral 
treatment groups, the PVD & Sham-LFMS group fluoresced the brightest indicating the most cell 
death. LFMS treatment significantly reduced cell death in the ipsilateral hippocampus. (c, d) The 
contralateral PVD & Sham-LFMS group displayed more cell death compared to the contralateral 
Sham-PVD & Sham-LFMS group. LFMS did not significantly reduce cell death in the 
contralateral hippocampus. n=3 independent experiments using four rats per experiment. Values 
are shown as mean + SEM. Significance values: *= p<0.05, **= p<0.01. 
3.4 LFMS on hippocampal neurodegeneration   
While PI confirmed that LFMS rescues hippocampal cells, FJC was specified whether 
these rescued cells were neurons. Hippocampal LTP is partly dependent on adenosine and 
glutamate signalling, the disturbance of which (by PVD) causes downstream neurodegeneration 
(Z. Chen et al., 2014; Lin & Koleske, 2010). Applying gamma oscillations have been found to 
affect neurons by restoring hippocampal LTP (Komaki, Khalili, Salehi, Shahidi, & Sarihi, 2014; 
Zhen et al., 2017). Whether this restoration prevents PVD-induced neurodegeneration remains 
unknown. In the current study, hippocampal slices were washed then stained with FJC for 20 
minutes. A Zeiss LSM700 laser scanning confocal microscope was used to image the stained 
slices. GBOs or LFMS was hypothesized to decrease hippocampal neurodegeneration following 
PVD.  
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The PVD & Sham-LFMS group displayed the largest percentage of hippocampal 
neurodegeneration compared to all other groups (Figure 3.7c, e). LFMS significantly prevented or 
inhibited this neurodegeneration (Figure 3.7d, e). In fact, the PVD & LFMS group was not 
significantly different compared to the two Sham-PVD groups, indicating close to full prevention 
of neurodegeneration by LFMS (Figure 3.7a, b, d, e). Unlike in the PI experiments, the ipsilateral 
and contralateral sides of the PVD lesion were not separated for FJC staining. Therefore, the 
different mechanisms and degrees of neuroprotection within each hemisphere cannot be 
distinguished. PVD-induced neurodegeneration is nonetheless very clear (Z. Chen et al., 2014). 
Again, more research must be done to understand how the synaptic changes that occur following 
PVD eventually lead to hippocampal neurodegeneration.  
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Figure 3.7 LFMS prevents hippocampal neurodegeneration following PVD. (a-e) Fixed 
hippocampal slices were stained with FJC then imaged with 10x and 63x lenses of a laser scanning 
confocal microscope. (a-d) The 10x images were combined to form a montage of the whole 
hippocampus on the left panel. The right panel contains combined Z-stack images of the CA1. (e) 
Bar graphs showing mean densitometry values normalized to the time control value (100%). (a-e) 
The PVD & Sham-LFMS group displayed the highest percentage of neurodegeneration compared 
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to all other groups. This degree of degeneration was significantly reduced in the PVD & LFMS 
group to the degree where its fluorescence was comparable (not significantly different) to the 
Sham-PVD groups. The ipsilateral and contralateral hippocampi were not separated in this 
experiment due to an experimental design error. n=3 independent experiments using four rats per 
experiment. Values are shown as mean + SEM. Significance values: *= p<0.05, **= p<0.01. 
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Chapter 4: Discussion 
4.1 LFMS improves emotional and cognitive impairments following PVD.  
4.1.1 LFMS alleviates depressive behaviour following PVD. 
The FST results indicate that there are strong links between PVD-induced adenosine and 
glutamate signaling, and depressive behaviour. Rats that underwent PVD and Sham-LFMS 
displayed the most immobility and the shortest latency to immobility compared to all other 
treatment groups. PVD causes global increases in extracellular adenosine leading to 
overstimulation and internalization of A1R; compensatory upregulation of A2AR; and 
downregulations of GluA1 and GluA2 in the rat hippocampus (Z. Chen et al., 2014). Similarly, 
A1R knockout mice display depressive behaviour and resistance to the antidepressant effects of 
sleep deprivation (Serchov et al., 2015), while overexpressing A2AR in the forebrain neurons of 
rats increases immobility in the FST and decreases sucrose preference at 48 hours in the sucrose 
preference test (Coelho et al., 2014). Although the literature is clear on how A1R and A2AR 
differentially regulate depression, it is less clear about non-selective antagonism. For example, 
caffeine was found to act through A2AR to prevent the mood and memory deficits triggered by 
chronic stress (Kaster et al., 2015). 
GBOs had significant effects on immobility scores in the FST. Compared to the PVD & 
Sham-LFMS group, rats that underwent PVD and LFMS treatment displayed smaller percentages 
of time spent immobile and longer latencies to immobility. Not only are hippocampal gamma 
oscillations disrupted following ischemic stroke, but various studies have reported that gamma 
oscillation patterns differ between depressed patients and healthy individuals (Akar, Kara, 
Agambayev, & Bilgic, 2015; Liao, Wu, Huang, Cheng, & Liu, 2017; Pizzagalli, Peccoralo, 
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Davidson, & Cohen, 2006; Siegle, Condray, Thase, Keshavan, & Steinhauer, 2010; Strelets, 
Garakh Zh, & Novototskii-Vlasov, 2007). PVD leads to persistent A1R stimulation. Similarly, 
administering adenosine kinase inhibitor 5-iodotubericidin, A1R agonist PIA, or A2AR antagonist 
ZM241385 suppressed kainaite-induced gamma oscillation power (Pietersen, Lancaster, Patel, 
Hamilton, & Vreugdenhil, 2009). Moreover, higher anti-depressant-induced gamma power across 
brain regions is associated with better response in depressive patients with lower baseline gamma 
power (Nugent et al., 2018). GBOs may be alleviating depressive behaviour by normalizing 
adenosine release following PVD, thereby reversing adenosine receptor remodeling, particularly 
A2AR upregulation.  
4.1.2 It remains unclear whether LFMS has an anxiolytic effect in PVD.  
Given the high comorbidity of depression and anxiety following a stroke (Schottke & 
Giabbiconi, 2015), it was hypothesized that the PVD & Sham-LFMS group would also display 
anxious behaviour in the OFT. However, there were no differences between the groups with 
regards to center square entries or center square durations. There was a trend where the PVD & 
Sham-LFMS group entered and stayed in the center square less compared to the other treatment 
groups. More n-values may be needed for these results to reach significance. According to the 
literature, the adenosine receptors are regulated differently in anxiety compared to depression. 
Both CPA and 2-chloro-N6-cyclopentyladenosine, a close analogue of CPA and another selective 
A1R agonist, were reported as anxiolytic in various behaviour tests (Florio, Prezioso, 
Papaioannou, & Vertua, 1998; Jain, Kemp, Adeyemo, Buchanan, & Stone, 1995; Prediger, da 
Silva, Batista, Bittencourt, & Takahashi, 2006). Overexpressing A2AR regardless of A1R in 
forebrain neurons also leads to anxiolytic effects indicated by hyperlocomotion and increased 
exploration (Coelho et al., 2014). PVD resembles both of these studies in that persistent A1R 
47 
 
stimulation results in the upregulation of A2AR (M. Chen et al., 2008). The LFMS results may 
provide a better explanation for PVD causing anxious behaviour in the current study contrary to 
the literature.  
GBOs did not significantly improve anxious behaviour in rats that underwent PVD. The 
PVD & LFMS group seemed to enter the center square more frequently and stay there for a longer 
duration compared to the PVD & Sham-LFMS group, however, these differences were not 
significant. Increased gamma oscillation power is associated with higher anxiety levels (Oathes et 
al., 2008). For instance, entering an anxious state results in increased gamma power that is 
prominent in the left temporal regions (Oathes et al., 2008). Moreover, those with generalized 
anxiety disorder who experience disproportionate worrying tend to exhibit increased gamma 
oscillation power during worrying compared to undiagnosed subjects (Oathes et al., 2008). Based 
on the locomotion and center square entries results, rats that received GBOs displayed increased 
excitability which may be due to an anxiolytic effect. PVD leads to increased adenosine release 
(Z. Chen et al., 2014), which is linearly related to hippocampal gamma oscillations (Pietersen et 
al., 2009). LFMS may be exerting its anxiolytic effects through dampening adenosine release 
following PVD rather than directly modulating the expressions of A1R and A2AR.  
4.1.3 LFMS may improve hippocampal-dependent spatial memory following PVD. 
Post-stroke hippocampal-dependent spatial memory was measured using novel arm 
duration in the Y-maze. The PVD & Sham-LFMS group spent significantly less time in the novel 
arm compared to the control group, represented by the double sham procedure. There was also a 
trend where the PVD & Sham-LFMS group had a smaller novel arm duration compared to the 
Sham-PVD & LFMS and PVD & LFMS groups. In one study, A1R knockout mice were reported 
to have unaffected spatial learning and CA1 synaptic potentiation (Gimenez-Llort et al., 2005). 
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However, another study showed that A2AR knockout mice had a higher percentage of novel arm 
visits indicating better hippocampal-dependent spatial memory compared to wild-type CD1 mice 
(J. H. Wang, Ma, & van den Buuse, 2006). These results indicate that adenosine signaling through 
A2AR may have a more direct effect on hippocampal-dependent spatial memory compared to A1R 
activity. PVD does in fact downregulate A2AR leading to glutamatergic changes that impair 
hippocampal synaptic plasticity (Z. Chen et al., 2014), which underlies processes such as learning 
and memory.  
Although there were no significant differences between the two PVD treatment groups, the 
PVD & LFMS group’s novel arm duration was more similar to the Sham-PVD & Sham-LFMS 
group compared to the PVD & Sham-LFMS group. These results indicate that LFMS has 
therapeutic potential in post-stroke hippocampal-dependent spatial memory deficits. Hippocampal 
gamma oscillations are important for various aspects of working memory. For example, cohesion 
in gamma oscillations across the hippocampus is present during object-location associative 
memory encoding (Trimper, Galloway, Jones, Mandi, & Manns, 2017). In another study, theta-
gamma oscillation coupling between the hippocampus and the medial prefrontal cortex was 
augmented during a spatial working memory task, in both cognitively impaired mice and wildtype 
mice performing in more difficult task settings (Tamura, Spellman, Rosen, Gogos, & Gordon, 
2017). Both A2AR agonism and A1R antagonism potentiate kainaite-induced gamma oscillations 
(Pietersen et al., 2009) in that same way that LFMS aims to increase or resynchronize gamma 
oscillations to improve cognitive performance following PVD. 
4.2 LFMS equalizes hemispheric differences in synaptic plasticity following PVD. 
The cLTP experiments assessed aspects of hippocampal synaptic plasticity. As LTP is the 
neuronal basis for learning and memory, these cLTP results support the findings in the Y-maze. 
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The contralateral PVD & Sham-LFMS group potentiated the most during cLTP and washout 
compared to both its ipsilateral counterpart and the Naïve & LFMS group. Thus, different 
mechanisms of synaptic plasticity are occurring in the ipsilateral and contralateral hippocampus 
following PVD. One of the best examples of hemispheric differences in plasticity following a 
stroke can be observed in the motor cortex. Contralateral motor cortex activation is substantially 
more pronounced compared to the ipsilateral, allowing for the reassignment of lost motor functions 
after a stroke (Chollet et al., 1991; Pekna, Pekny, & Nilsson, 2012; Zemke, Heagerty, Lee, & 
Cramer, 2003). Overall, this difference does not compensate well enough to compare to the ability 
of healthy controls. In the current study, the PVD & Sham-LFMS rats displayed significant 
impairments in hippocampal-dependent spatial memory compared to the Sham-PVD & Sham-
LFMS group 
There were no differences between the ipsilateral and contralateral PVD & LFMS groups 
during either cLTP or washout. However, there was a trend where the ipsilateral group was 
potentiated more during cLTP. The Naïve & LFMS group also reached higher fEPSPs during cLTP 
and washout compared to the two PVD & LFMS groups, however, this difference was not 
significant. These results indicate that GBOs may be equalizing PVD-induced the hemispheric 
differences. The mechanism of this equalizing effect is unknown. When the network oscillation 
tracks between the hemispheres are ever disrupted, the right hippocampus assumes a dominant 
compensatory role in merging the gamma oscillations from each hemisphere and feeding them to 
neuronal populations with inputs to both (Benito, Martin-Vazquez, Makarova, Makarov, & 
Herreras, 2016). Thus, GBOs may primarily be working through the right hippocampus in PVD, 
which may have compromised these tracks.  
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Overall, the differences in fEPSP during cLTP and washout were not distinguishable by 
LFMS or Sham-LFMS treatment. Although there was a trend where the ipsilateral and 
contralateral PVD & Sham-LFMS groups potentiated more during cLTP compared to the two PVD 
& LFMS groups, this difference was not significant. Both PVD and LFMS have mechanistic links 
to adenosine signaling and gamma oscillations. As PVD persistent stimulates A1R to disrupt LTP, 
it may also be suppressing gamma oscillations to impair hippocampal-dependent spatial memory. 
Moreover, A1R agonism and A2AR antagonism suppresses gamma oscillations, while A1R 
antagonism and A2AR agonism potentiates gamma oscillations (Pietersen et al., 2009). As 
previously mentioned, LFMS may be increasing and resynchronizing gamma oscillations 
following PVD. Pertaining to the cLTP results of the Naïve & LFMS group, the current study does 
not show differences or advantages in hippocampal spatial memory between the control group and 
Sham-PVD & LFMS group. However, other studies have shown that TMS delivering frequencies 
in the 10-20 Hz range enables healthy subjects to continually meet the increasing cognitive 
demands within a working memory task (Barr et al., 2009; Tamura et al., 2017). 
4.3 LFMS employs hemispherically different mechanisms to rescue non-discriminant cells in the 
hippocampus. 
PI staining was conducted to measure non-discriminant cell death in the hippocampus. As 
hypothesized, the ipsilateral PVD & Sham-LFMS group displayed the most cell death amongst the 
ipsilateral treatment groups. The contralateral PVD & Sham-PVD group displayed more cell death 
than only the contralateral Sham-PVD & Sham-PVD. There was no significant difference in cell 
death between the two contralateral PVD groups. These results support the hemispheric differences 
in the cLTP data. The synaptic potentiation mechanisms in the ipsilateral hippocampus rescuing 
more cells compared to the mechanisms occurring in the contralateral hippocampus. In past 
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experiments when hippocampal slices are exposed to either hypoxia or CPA, both manipulations 
cause cell death that was reversible by A1R antagonist DPCPX (Stockwell et al., 2016). Thus, 
GBOs may primarily be targeting persistent A1R stimulation to rescue non-discriminant cells in 
the hippocampus.   
4.4 LFMS reduces hippocampal neurodegeneration. 
The hemispheres were not separated prior to FJC staining. Therefore, this data set cannot 
support the cLTP data showing hemispheric differences in synaptic plasticity. Nonetheless, the 
PVD & Sham-LFMS group showed significant neurodegeneration, which had been shown in the 
past (Z. Chen et al., 2014). As it relates to neuroinflammation, the infiltration of peripheral immune 
cells following an ischemic stroke is thought to exacerbate secondary neurodegeneration. There is 
greater immune cell infiltration and subsequent neurodegeneration in ipsilateral compared to the 
contralateral brain regions (Jones et al., 2018). PVD upregulates A2AR, which is also implicated 
in neuroinflammation. Administering A2AR antagonist SCH58261 attenuates lipopolysaccharide-
induced inflammatory mediators and prevents biochemical changes, which otherwise decreased 
hippocampal LTP (Rebola et al., 2011). Future LFMS studies may delineate the relationships 
between A1R-modulated neurodegeneration and neuroinflammation in the PVD model.  
4.5 Limitations 
Acknowledging the limitations of the current study will guide future experiments and 
further our understanding of how GBOs are therapeutic in post-stroke conditions. The current 
study only used Sprague Dawley rats that were young adult males. This demographic represents a 
very small proportion of people who suffer from ischemic stroke. Future studies should also 
include females and rats of older ages. When it came to the LFMS treatment, it only adopted one 
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set of stimulation parameters. As previously mentioned, the frequency and temporal pattern, and 
total time per treatment session may be targeting specific regions and populations of cells more 
than others. Research on NIBS should focus on adjusting these parameters to target specific aspects 
of pathophysiology and symptoms. This leads to the experimental design, which measures LFMS-
induced behavioral and cellular changes after three days of once-daily LFMS treatments. This is 
considered short-term and does not imply that these three treatment sessions have sustained 
therapeutic effects. Future studies should at least continue behaviour testing throughout the month 
following the PVD and treatments to measure long-term sustainability. Related to behaviour 
testing, more tests should have been conducted for each psychiatric symptom. For example, the 
sucrose preference test, Morris water test, and elevated plus maze are additional ways to measure 
depression, anxiety, and hippocampal-dependent spatial memory, respectively. Related to the 
treatment groups in the current study, the Naïve & LFMS group was only part of the cLTP 
experiments. Along with this treatment group, there should also have been a Naïve & Sham-LFMS 
group to confirm that Sham-PVD surgery has no significant effects on any of the experiments or 
responding variables. Lastly, the current study lacked groups representing adenosine receptor 
antagonism. By having a PVD & A1R antagonist (i.e. DPCPX) group and comparing it to the PVD 
& LFMS group, the therapeutic effects of LFMS could have been attributed to changes in 
adenosine signaling. This is imperative for future studies, to be able to make correlational links 
between GBOs or LFMS and adenosine signaling. 
4.6 Future Directions 
Related to the limitations described in the previous section, the current three-day 
experimental timeline can be adapted for further pharmacological analysis. By administering an 
A1R antagonist at the time of the PVD surgery and throughout the rest of the experimental 
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timeline, persistent A1R stimulation resulting in its desensitization and subsequent adenosine-
mediated glutamatergic modulation may be eliminated. Similarly, an A2AR antagonism may 
prevent the compensatory upregulation in A2AR surface expression and activity. Based on 
previous studies, antagonizing these receptors is expected to inhibit adenosine-mediated AMPA 
receptor subunit internalization leading to LTD and impairments in behaviour (Z. Chen et al., 
2014; Stockwell et al., 2016). Interestingly, A1R antagonism has been shown to increase the power 
of endogenous gamma oscillations, while A2AR antagonism is thought to decrease this power 
(Pietersen et al., 2009). Incorporating either selective or non-selective adenosine antagonism in the 
current experimental design may better isolate the molecular targets of LFMS in the context of 
PVD-induced gamma oscillations and intracellular signalling. Aside from receptor activity, PVD-
induced extracellular adenosine concentration can also be investigated as a potential therapeutic 
target. This concentration is measurable via electrophysiological techniques entailing 
microelectrode biosensors at the level of acute brain slices (Wall, Atterbury, & Dale, 2007). Future 
studies can also adapt various spatial, temporal, and electromagnetic parameters of the LFMS 
machine. Different timelines, such as shorter or longer stimulation periods or latencies till 
behaviour and post-mortem experimentation, may yield valuable pre-clinical information. 
The therapeutic potential of LFMS in PVD can be studied in various physiological and 
anatomical angles. Major stroke-induced pathophysiological processes include excitotoxicity, 
oxidative stress, neurodegeneration (apoptosis and necrosis), and neuroinflammation (Deb, 
Sharma, & Hassan, 2010). Occurring concomitantly are repair mechanisms such as neurogenesis, 
synaptogenesis, oligodendrogenesis, and astroglioses (R. L. Zhang et al., 2012). Future PVD and 
LFMS experiments can cellularly and molecularly target any of these processes to better 
understand the therapeutic mechanism of LFMS. Future studies can also investigate different brain 
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regions implicated in cardiovascular-related emotional and cognitive impairments, as well as 
regions that are concentrated with A1R and A2AR. Limbic and cortical structures are of particular 
importance when it comes to depression and anxiety. The frontal-basal ganglia pathway may also 
be important as it facilitates serotonergic, adrenergic, and dopaminergic neurotransmission (J. S. 
Kim & Choi-Kwon, 2000). Aside from grey matter, post-PVD white matter may also contain clues 
about therapeutic mechanism. White matter comprises of axon bundles, myelin and 
oligodendrocytes. White matter abnormalities in the form of hyperintensities are very common in 
ischemic stroke and can predict recurrent strokes as well as vascular depression and dementia 
(Gootjes et al., 2004; Leys et al., 1999). Thus, future studies can also assess whether LFMS is 
neuroprotective against ischemia through oligodendrogenesis (R. Zhang, Chopp, & Zhang, 2013).  
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Chapter 5: Conclusion 
Based on the findings in the current study, three days of once-daily GBOs following a focal 
cortical ischemic stroke improved certain aspects of post-stroke emotional and cognitive 
impairments. Rats that underwent PVD and LFMS displayed less depressive behaviour and 
restored hippocampal-dependent spatial memory. As for anxiety, there was a trend where LFMS 
was anxiolytic in rats experiencing PSA. The FST and Y-maze results support the hypothesis that 
GBOs delivered by LFMS reverses the changes in adenosine signaling caused by PVD. These 
changes are due to persistent A1R stimulation resulting in its internalization and the subsequent 
upregulation of A2AR. Based on the literature on adenosine and anxiety, however, increased A1R 
and decreased A2AR stimulation were expected to be anxiolytic rather than anxiogenic. Thus, 
LFMS may also have a normalizing effect on any excessive gamma oscillations as a result of PVD, 
thereby preventing receptor modelling, particularly A1R internalization. When it came to the cLTP 
experiments, LFMS equalized stroke-induced hemispheric differences in fEPSPs during the 
induction and washout periods. In other words, GBOs decreased contralateral fEPSPs resulting in 
the abolishment of its excitotoxic compensatory mechanisms, while improving ipsilateral synaptic 
plasticity or LTP. Finally, LFMS rescued cells and lessened neurodegeneration in the 
hippocampus. 
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